Ccr5 - chemokine (C-C motif) receptor 5 Gene

Also Known as AM4-7; CD195; Cmkbr5

Species: Mus musculus

Gene Type: protein coding
Gene ID: 12774

About Ccr5

Chromosome 9: 123,921,580-123,947,736 forward strand.GRCm39:CM001002.3

This gene has 6 transcripts (splice variants), 151 orthologues, 25 paralogues and is associated with 50 phenotypes. Ubiquitous expression in subcutaneous fat pad adult (RPKM 2.2), mammary gland adult (RPKM 2.1) and 27 other tissues.

Summary

Enables C-C chemokine binding activity and C-C Chemokine Receptor activity. Involved in negative regulation of macrophage apoptotic process. Acts upstream of or within defense response. Located in external side of plasma membrane. Is expressed in several structures, including alimentary system; brain; hemolymphoid system gland; liver and biliary system; and reproductive system. Used to study Coronavirus infectious disease. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; West Nile fever; autoimmune disease (multiple); berylliosis; and sarcoidosis (multiple). Orthologous to human CCR5 (C-C motif Chemokine Receptor 5). [provided by Alliance of Genome Resources, Apr 2022]

Ccr5 Products (1)

mRNA Protein Name
NM_009917.5 NP_034047.2 C-C chemokine receptor type 5

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables C-C chemokine binding IPI
IPI: Inferred from physical interaction
9139699 MGI
enables C-C chemokine receptor activity IDA
IDA: Inferred from direct assay
8631787 MGI
Biological Process GO Annotation Evidence References Source
acts upstream of or within apoptotic process IMP
IMP: Inferred from mutant phenotype
36301669 MGI
acts upstream of or within defense response IMP
IMP: Inferred from mutant phenotype
10528159 MGI
involved in negative regulation of macrophage apoptotic process IDA
IDA: Inferred from direct assay
16208318 MGI
Cellular Component GO Annotation Evidence References Source
located in cell surface IDA
IDA: Inferred from direct assay
23620790 MGI
located in external side of plasma membrane IDA
IDA: Inferred from direct assay
16301745 MGI
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

Ccr5 Protein Structure

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (32 - 59)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (32 - 309)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (66 - 91)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (102 - 132)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (144 - 166)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (192 - 221)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (229 - 259)

7tmA_CCR5_CCR2

7tmA_CCR5_CCR2: cd15184 (277 - 302)

  • 0
  • 100
  • 200
  • 300
  • 354 a.a.
Protein Preferred Names Protein Names

C-C chemokine receptor type 5

  • C-C CKR-5

  • CC-CKR-5

  • CCR-5

  • MIP-1 alpha receptor

  • chemokine (C-C) receptor 5

Recombinant Ccr5 Proteins

Cat. No. Product Name Accession Purity
HY-P700540 CCR5 Protein, Mouse (P. pastoris, His) P51682 (Q263-L354) ≥ 90%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-13004 Maraviroc Antagonist 99.98% Yes
HY-117621A PF-04634817 succinate Antagonist 99.50% Unkown
HY-117621 PF-04634817 Antagonist 98.87% Unkown

Clinical Phase

Bioactive Molecules (11)
Cat. No. Product Name Effect
Purity Phase
HY-14882 Cenicriviroc Antagonist 99.51% Phase 3
HY-14882A Cenicriviroc Mesylate Antagonist 99.94% Phase 3
HY-17377 Vicriviroc maleate Antagonist 99.91% Phase 3
HY-17450A Aplaviroc hydrochloride Antagonist 99.94% Phase 3
HY-17450 Aplaviroc Antagonist / Phase 3
HY-118962 E913 Antagonist / Phase 3
HY-P1034 DAPTA Inhibitor 99.40% Phase 2
HY-109593 BMS-813160 Antagonist 99.93% Phase 2
HY-101713 Ilacirnon Inhibitor 98.05% Phase 2
HY-14230 INCB9471 Antagonist / Phase 2
HY-19974 TAK-220 Antagonist 99.95% Phase 1

Pre-clinical Phase

Bioactive Molecules (16)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-13406 TAK-779 Antagonist 99.89% Unkown
HY-P4191A Met-RANTES (human) acetate Antagonist 99.39% Unkown
HY-111069 Nifeviroc Inhibitor 99.39% Unkown
HY-119101 AZD-5672 Antagonist 95.74% Unkown
HY-P4191 Met-RANTES (human) Antagonist / Unkown
HY-100261 CCR5 antagonist 1 Antagonist / Unkown
HY-107401 Ancriviroc Antagonist / Unkown
HY-152131 CCR5 antagonist 2 Antagonist / Unkown
HY-123902 Ophiobolin C Inhibitor / Unkown
HY-179607 LUF8100 Antagonist 98.64% Unkown
HY-111321 Fuscin Inhibitor / Unkown
HY-108432 BMS-741672 Antagonist / Unkown
HY-152132 CCR5 antagonist 3 Inhibitor / Unkown
HY-103406 PNU-177864 Inhibitor / Unkown
HY-162512 CB-0821 Inhibitor / Unkown
HY-119658 PF-4178903 Antagonist / Unkown
Inhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P991653 HGS004 Inhibitor / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Ccr5 NCBI NCBI:1234